左心室の障害に対する抗血栓剤は?

Same author

Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.

Current opinion in cardiology·2001

Same author

Antithrombotic agents in coronary artery disease.

Chest·2001

Same author

In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents.

Cardiovascular research·2000

Same author

Labelling of platelets with indium-111 oxine and technetium-99m hexamethylpropylene amine oxime: suggested methods. International Society of Radiolabelled Blood Elements (ISORBE).

European journal of nuclear medicine·2000

Same author

Antithrombotic agents in coronary artery disease.

Chest·1998

Same author

Minimally invasive coronary artery bypass grafting: initial Connecticut experience.

Connecticut medicine·1997

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

左心室の障害に対する抗血栓剤は?

関連する概念動画

Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.

Antithrombotic agents in coronary artery disease.

In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents.

Labelling of platelets with indium-111 oxine and technetium-99m hexamethylpropylene amine oxime: suggested methods. International Society of Radiolabelled Blood Elements (ISORBE).

Antithrombotic agents in coronary artery disease.

Minimally invasive coronary artery bypass grafting: initial Connecticut experience.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

左心室の障害に対する抗血栓剤は?

関連する概念動画

関連記事

Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.

Antithrombotic agents in coronary artery disease.

In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents.

Labelling of platelets with indium-111 oxine and technetium-99m hexamethylpropylene amine oxime: suggested methods. International Society of Radiolabelled Blood Elements (ISORBE).

Antithrombotic agents in coronary artery disease.

Minimally invasive coronary artery bypass grafting: initial Connecticut experience.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.